High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis #
Top Cited Papers
Open Access
- 27 August 2009
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 50 (3), 808-814
- https://doi.org/10.1002/hep.23082
Abstract
Previous controlled trials are inconclusive regarding the efficacy of ursodeoxycholic acid (UDCA) for treating primary sclerosing cholangitis (PSC). One hundred fifty adult patients with PSC were enrolled in a long-term, randomized, double-blind controlled trial of high-dose UDCA (28-30 mg/kg/day) versus placebo. Liver biopsy and cholangiography were performed before randomization and after 5 years. The primary outcome measures were development of cirrhosis, varices, cholangiocarcinoma, liver transplantation, or death. The study was terminated after 6 years due to futility. At enrollment, the UDCA (n = 76) and placebo (n = 74) groups were similar with respect to sex, age, duration of disease, serum aspartate aminotransferase and alkaline phosphatase levels, liver histology, and Mayo risk score. During therapy, aspartate aminotransferase and alkaline phosphatase levels decreased more in the UDCA group than the placebo group (P < 0.01), but improvements in liver tests were not associated with decreased endpoints. By the end of the study, 30 patients in the UDCA group (39%) versus 19 patients in the placebo group (26%) had reached one of the pre-established clinical endpoints. After adjustment for baseline stratification characteristics, the risk of a primary endpoint was 2.3 times greater for patients on UDCA than for those on placebo (P < 0.01) and 2.1 times greater for death, transplantation, or minimal listing criteria (P = 0.038). Serious adverse events were more common in the UDCA group than the placebo group (63% versus 37% [P < 0.01]). Conclusion: Long-term, high-dose UDCA therapy is associated with improvement in serum liver tests in PSC but does not improve survival and was associated with higher rates of serious adverse events. (Hepatology 2009.)Keywords
This publication has 19 references indexed in Scilit:
- High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effectiveJournal of Hepatology, 2008
- Tacrolimus for the treatment of primary sclerosing cholangitisLiver International, 2007
- High-Dose Ursodeoxycholic Acid in Primary Sclerosing Cholangitis: A 5-Year Multicenter, Randomized, Controlled StudyGastroenterology, 2005
- A Revised Natural History Model for Primary Sclerosing CholangitisMayo Clinic Proceedings, 2000
- A Revised Natural History Model for Primary Sclerosing CholangitisMayo Clinic Proceedings, 2000
- A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation.Journal of Clinical Investigation, 1998
- Cytotoxicity of bile salts against biliary epithelium: A study in isolated bile ductule fragments and isolated perfused rat liverHepatology, 1997
- Ursodiol for Primary Sclerosing CholangitisNew England Journal of Medicine, 1997
- Colchicine treatment of primary sclerosing cholangitisGastroenterology, 1995
- Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin.Gut, 1993